Antiviral activity of an ACE2-Fc fusion protein against SARS-CoV-2 and its variants
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0312402 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Ernesto Bermúdez-Abreut und 11 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Immunotherapy Division, Center of Molecular Immunology (CIM), Havana, Cuba. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, SARS-CoV-2, Recombinant Fusion Proteins, Immunoglobulin Fc Fragments. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
SARS-CoV-2 has continued spreading around the world in recent years since the initial outbreak in 2019, frequently developing into new variants with greater human infectious capacity. SARS-CoV-2 and its mutants use the angiotensin-converting enzyme 2 (ACE2) as a cellular entry receptor, which has triggered several therapeutic strategies against COVID-19 relying on the use of ACE2 recombinant proteins as decoy receptors. In this work, we propose an ACE2 silent Fc fusion protein (ACE2-hFcLALA) as a candidate therapy against COVID-19. This fusion protein was able to block the binding of SARS-CoV-2 RBD to ACE2 receptor as measured by ELISA and flow cytometry inhibition assays. Moreover, we used classical neutralization assays and a progeny neutralization assay to show that the ACE2-hFcLALA fusion protein is capable of neutralizing the authentic virus. Additionally, we found that this fusion protein was more effective in preventing in vitro infection with different variants of interest ( alpha , beta , delta , and omicron ) compared to the D614G strain. Our results suggest the potential of this molecule to be used in both therapeutic and preventive settings against current and emerging mutants that use ACE2 as a gateway to human cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Immunology and Immunotherapy Division, Center of Molecular Immunology (CIM), Havana, Cuba.
- National Laboratory of Civil Defense (NLCD), Jamaica Highway and National Highway, San José of Lajas, Mayabeque, Cuba.
ORCID-Profile: Ernesto Bermúdez-Abreut, Briandy Fernández-Marrero
Zitieren
APA
Bermúdez-Abreut, E., Fundora-Barrios, T., Hernández Fernández, D. R., Noa Romero, E., Fraga-Quintero, A., Casadesús Pazos, A. V., Fernández-Marrero, B., Plasencia Iglesias, C. A., Clavel Pérez, M., Sosa Aguiar, K., Sánchez-Ramírez, B., & Hernández, T. (2025). Antiviral activity of an ACE2-Fc fusion protein against SARS-CoV-2 and its variants. PLOS ONE. https://doi.org/10.1371/journal.pone.0312402
Vancouver
Bermúdez-Abreut E, Fundora-Barrios T, Hernández Fernández DR, Noa Romero E, Fraga-Quintero A, Casadesús Pazos AV, et al. Antiviral activity of an ACE2-Fc fusion protein against SARS-CoV-2 and its variants. PLOS ONE. 2025. doi:10.1371/journal.pone.0312402
BibTeX
@article{BermdezAbreut2025,
author = {Bermúdez-Abreut, Ernesto and Fundora-Barrios, Talia and Hernández Fernández, Diana Rosa and Noa Romero, Enrique and Fraga-Quintero, Anitza and Casadesús Pazos, Ana V and Fernández-Marrero, Briandy and Plasencia Iglesias, Claudia A and Clavel Pérez, Marilyn and Sosa Aguiar, Katya and Sánchez-Ramírez, Belinda and Hernández, Tays},
title = {Antiviral activity of an ACE2-Fc fusion protein against SARS-CoV-2 and its variants},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0312402}
}
EUVIMED